BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

857 related articles for article (PubMed ID: 19010377)

  • 21. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane.
    Lyu YL; Kerrigan JE; Lin CP; Azarova AM; Tsai YC; Ban Y; Liu LF
    Cancer Res; 2007 Sep; 67(18):8839-46. PubMed ID: 17875725
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-lasting effect of dexrazoxane against anthracycline cardiotoxicity in rats.
    Della Torre P; Podesta A; Pinciroli G; Iatropoulos MJ; Mazué G
    Toxicol Pathol; 1996; 24(4):398-402. PubMed ID: 8864181
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Dexrazoxane (ICRF-187)--a cardioprotectant and modulator of action of some anticancer drugs].
    Kik K; Szmigiero L
    Postepy Hig Med Dosw (Online); 2006; 60():584-90. PubMed ID: 17115008
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase IIβ inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity.
    Bavlovič Piskáčková H; Jansová H; Kubeš J; Karabanovich G; Váňová N; Kollárová-Brázdová P; Melnikova I; Jirkovská A; Lenčová-Popelová O; Chládek J; Roh J; Šimůnek T; Štěrba M; Štěrbová-Kovaříková P
    Sci Rep; 2021 Feb; 11(1):4456. PubMed ID: 33627707
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathogenesis and prevention of doxorubicin cardiomyopathy.
    Ferrans VJ; Clark JR; Zhang J; Yu ZX; Herman EH
    Tsitologiia; 1997; 39(10):928-37. PubMed ID: 9505340
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A QSAR study that compares the ability of bisdioxopiperazine analogs of the doxorubicin cardioprotective agent dexrazoxane (ICRF-187) to protect myocytes with DNA topoisomerase II inhibition.
    Hasinoff BB; Patel D; Wu X
    Toxicol Appl Pharmacol; 2020 Jul; 399():115038. PubMed ID: 32417440
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice.
    Bruynzeel AM; Mul PP; Berkhof J; Bast A; Niessen HW; van der Vijgh WJ
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):699-702. PubMed ID: 16565833
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytoprotective agents for anthracyclines.
    Dorr RT
    Semin Oncol; 1996 Aug; 23(4 Suppl 8):23-34. PubMed ID: 8783663
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase II
    Kollárová-Brázdová P; Jirkovská A; Karabanovich G; Pokorná Z; Bavlovič Piskáčková H; Jirkovský E; Kubeš J; Lenčová-Popelová O; Mazurová Y; Adamcová M; Skalická V; Štěrbová-Kovaříková P; Roh J; Šimůnek T; Štěrba M
    J Pharmacol Exp Ther; 2020 Jun; 373(3):402-415. PubMed ID: 32253261
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of bisdioxopiperazine dexrazoxane binding to human DNA topoisomerase II alpha: decreased binding as a mechanism of drug resistance.
    Renodon-Cornière A; Jensen LH; Nitiss JL; Jensen PB; Sehested M
    Biochemistry; 2003 Aug; 42(32):9749-54. PubMed ID: 12911317
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical pharmacology of dexrazoxane.
    Hochster HS
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):37-42. PubMed ID: 9768822
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the protective effects of desferrioxamine and ICRF-187 against doxorubicin-induced toxicity in spontaneously hypertensive rats.
    Herman EH; Zhang J; Ferrans VJ
    Cancer Chemother Pharmacol; 1994; 35(2):93-100. PubMed ID: 7987999
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The iron chelator Dp44mT does not protect myocytes against doxorubicin.
    Hasinoff BB; Patel D
    J Inorg Biochem; 2009 Jul; 103(7):1093-101. PubMed ID: 19535146
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines.
    Rothenborg-Jensen L; Hansen HF; Wessel I; Nitiss JL; Schmidt G; Jensen PB; Sehested M; Jensen LH
    Anticancer Drug Des; 2001 Dec; 16(6):305-15. PubMed ID: 12375883
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preclinical animal models of cardiac protection from anthracycline-induced cardiotoxicity.
    Herman EH; Ferrans VJ
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):15-21. PubMed ID: 9768819
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dendritic cells in the hearts of spontaneously hypertensive rats treated with doxorubicin with or without ICRF-187.
    Zhang J; Herman EH; Ferrans VJ
    Am J Pathol; 1993 Jun; 142(6):1916-26. PubMed ID: 8506959
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?
    Hasinoff BB; Herman EH
    Cardiovasc Toxicol; 2007; 7(2):140-4. PubMed ID: 17652819
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces endopolyploidy in Chinese hamster ovary cells.
    Hasinoff BB; Abram ME; Chee GL; Huebner E; Byard EH; Barnabé N; Ferrans VJ; Yu ZX; Yalowich JC
    J Pharmacol Exp Ther; 2000 Nov; 295(2):474-83. PubMed ID: 11046078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The protective effect of cardiac gene transfer of CuZn-sod in comparison with the cardioprotector monohydroxyethylrutoside against doxorubicin-induced cardiotoxicity in cultured cells.
    Abou El Hassan MA; Heijn M; Rabelink MJ; van der Vijgh WJ; Bast A; Hoeben RC
    Cancer Gene Ther; 2003 Apr; 10(4):270-7. PubMed ID: 12679799
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemistry of dexrazoxane and analogues.
    Hasinoff BB
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):3-9. PubMed ID: 9768817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.